Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Abstract Background Revefenacin is a long-acting muscarinic antagonist that was recently approved for the nebulized treatment of chronic obstructive pulmonary disease (COPD). Although shorter duration studies have documented the efficacy of revefenacin in COPD, longer-term efficacy has not been desc...

Full description

Bibliographic Details
Main Authors: James F. Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, Glenn Crater
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Respiratory Research
Online Access:http://link.springer.com/article/10.1186/s12931-019-1187-7

Internet

http://link.springer.com/article/10.1186/s12931-019-1187-7

Similar Items